A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Bioequivalence Study of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville Under Fasted Condition in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 17 May 2011
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics; Registrational
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 27 Nov 2008 New trial record.